COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (based on the Ministry of Health protocol: hydroxychloroquine etc,..), patients will receive 1 puff (e
Sponsors
CinnaGen company
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients who have Covid-19 based on the CT-scan or RT-PCR findings Hospitalized patients Willingness to participate in the study for trial period and signing the informed consent form Age between 20-65
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding Use of ARB/ACEi History of hypotension have no consent to participate in the study Allergic sensitivity to the interferon products Not availability of phone number or it is possible to be transferred to other hospitals Having the CKD or patients who need dialysis at the begining of the study Having any disease or condition that based on the physician judgment cannot participate in the study Participation in any other trials of Covid-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was the evaluation of 50% reduction of viral load or negative results of virus before day 7. Timepoint: before drug administration, day 3, day 5, and day 7 (before negative result until day 7). Method of measurement: RT-PCR test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of days with fever (more than 37.2) up to 7 days. Timepoint: Daily up to day 7. Method of measurement: Thermometer.;Number of days with dyspnea until day 7. Timepoint: Daily up to day 7. Method of measurement: Clinical examination by investigator or history review of the patients.;Number of days that patients need supplemental oxygenation up to day 7. Timepoint: Daily up to day 7. Method of measurement: Examination by investigator.;Change of laboratory results of patients before treatment and last day of study (day 7). Timepoint: Before drug administration and last day of study. Method of measurement: Laboratory results.;Adverse events. Timepoint: Daily up to day 7. Method of measurement: Investigator report.;Number of days that patients have dry cough. Timepoint: Daily until day 7. Method of measurement: Examination by investigator. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAshraf Karbasi
Bagheiat-allah University of Medical Sciences
Outcome results
None listed